logo
logo

Gliknik Inc. Raises $11.5 Million In Series C Financing

Jun 24, 2021•about 4 years ago

Amount Raised

$11.5 Million

Round Type

series c

Baltimore

Description

Gliknik Inc., an immunology company dedicated to patients with cancer and autoimmune disorders, today announced that it has successfully completed an $11.5 million Series C Preferred Stock financing. First In Ventures (FIV) led the Series C with SAISO Partners and affiliates of RDA Ventures and Garden Street Holdings also participating. The proceeds are targeted to progress the growing pipeline of Gliknik product candidates. Gliknik has secured $81 million to date to advance its programs.

Company Information

Company

Gliknik

Location

Baltimore, Maryland, United States

About

Gliknik is an immunology company creating and advancing biologic drugs for patients with cancer and autoimmune disorders. Learn more at www.gliknik.com. This press release contains “forward-looking statements” concerning the development and commercialization of Gliknik products, the potential benefits and attributes of such products, and Gliknik expectations regarding its prospects. Forward-looking statements are subject to risks, assumptions and uncertainties that could cause actual future events or results to differ materially from such statements. These statements are made as of the date of this press release. Actual results may vary. Gliknik undertakes no obligation to update any forward-looking statements for any reason.

Funding Insights

Based on industry data
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech